News

Sonnet Releases Virtual Investor "What This Means" Segment
Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data ...
Hosted on MSN13d
Anthropic to create more than 100 roles in Europe
The company launched Claude 3.7 Sonnet, its latest hybrid reasoning model in February ... "Anthropic to create more than 100 ...
Seeking Alpha17d
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at ...
“This topline safety data release from our atezolizumab combination program is another significant milestone for Sonnet’s clinical development,” concluded Raghu Rao, Sonnet’s Interim Chief ...
Yahoo Finance26d
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
PRINCETON, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company ...
Business Insider26d
Sonnet BioTherapeutics completes first safety review of SON-1010
Sonnet BioTherapeutics (SONN) announced positive findings from the first safety review of the expansion cohort in its Phase 1 SB101 clinical trial evaluating SON-1010, the Company’s proprietary ...
CNN4y
Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a ...